Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

← catalyst calendar

NCT07704658 · readout in 344 d

Sponsored by Rigel Pharmaceuticals (industry) · RIGL — their whole pipeline →.

Phase

Phase 4

Status

Recruiting

Study type

Interventional

Design

Na · None · Other

Enrollment

12estimated

Sites

Country

Spain

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-03-04

actual

When the study began enrolling

Primary completion

2027-07-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-08-30

estimated

The whole study's end, after follow-up

First posted

2026-07-15

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-10

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

NSCLC (Non-small Cell Lung Cancer)
Thyroid Cancer
Solid Tumor Malignancies
Advanced Malignancies

Interventions

Drug: Pralsetinib
Drug: CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive

Primary outcomes

what the primary-completion date above is the date OF

Area Under the Plasma Concentration-Time Curve from zero to infinity (AUC0-inf)

measured Up to 48 hours post-dose or as appropriate for each probe substrate

Area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUClast)

measured Up to 48 hours after each probe drug administration

Maximum Peak Plasma Concentration (Cmax)

measured Up to 48 hours after each probe drug administration

Permalink · RIGL's whole pipeline · Catalyst calendar · Every registered study · What changed